C. Gaul

发表

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Eric Vangrevelinghe, Andrew L. Kung, James E. Bradner, 2011, The Journal of experimental medicine.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer cell.

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

A. Letai, S. Sallan, M. Harris, 2015, Cancer cell.

Synthetic analogues of migrastatin that inhibit mammary tumor metastasis in mice.

Lin Chen, Xiaojing Ma, Xin-Yun Huang, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Confirmation of the Structures of Synthetic Derivatives of Migrastatin in the Light of Recently Disclosed Crystallographically Based Claims.

O. Ouerfelli, S. Danishefsky, J. T. Njardarson, 2010, Tetrahedron letters.

The total synthesis of (+)-migrastatin.

S. Danishefsky, J. T. Njardarson, C. Gaul, 2003, Journal of the American Chemical Society.

Synthesis of the macrolide core of migrastatin

S. Danishefsky, C. Gaul, 2002 .

New Potent DOT1L Inhibitors for in Vivo Evaluation in Mouse.

R. Tiedt, D. Guthy, C. Scheufler, 2019, ACS medicinal chemistry letters.

Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts.

S. Armstrong, R. Tiedt, A. Krivtsov, 2020, Blood.

Identification of orally available naphthyridine protein kinase D inhibitors.

I. Enyedy, T. McKinsey, Margaret R Pancost, 2010, Journal of medicinal chemistry.

Effects of temperature and concentration in some ring closing metathesis reactions

S. Danishefsky, C. Gaul, Kaustav Biswas, 2003 .

Metallations and Reactions with Electrophiles of 4-Isopropyl-5,5-diphenyloxazolidin-2-one (DIOZ) with N-Allyl and N-Propargyl Substituents: Chiral Homoenolate Reagents

D. Seebach, C. Gaul, 2002 .

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

Applications of the Chiral Auxiliaries DIOZ and TRIOZ for Conjugate Additions and Comparison with Other Auxiliaries

D. Seebach, R. Marti, A. Beck, 2010 .

Crystal Structures - A Manifesto for the Superiority of the Valine-Derived 5,5-Diphenyloxazolidinone as an Auxiliary in Enantioselective Organic Synthesis

D. Seebach, B. Schweizer, P. Seiler, 2002 .

Conjugate Addition of Lithiated (S)-4-Isopropyl-3-[(methylthio)methyl]-5,5-diphenyloxazolidin-2-one to Cinnamoyl Derivatives: Preparation of Enantiomerically Pure 1,4-Diols

D. Seebach, C. Gaul, 2002 .

Lithiated 4-isopropyl-3-(methylthiomethyl)-5,5-diphenyloxazolidin-2-one: a chiral formyl anion equivalent for enantioselective preparations of 1,2-diols, 2-amino alcohols, 2-hydroxy esters, and 4-hydroxy-2-alkenoates.

D. Seebach, C. Gaul, K. Schärer, 2001, The Journal of organic chemistry.

En route to the total synthesis of tashironin: on the exercise of stereochemical control by a methyl group in mediating remote cyclization reactions

S. Danishefsky, C. Gaul, S. Cook, 2005 .

Computational, ReactIR-, and NMR-spectroscopic investigations on the chiral formyl anion equivalent N-(alpha-lithiomethylthiomethyl)-4-isopropyl-5,5-diphenyloxazolidin-2-one and related compounds.

D. Seebach, P. Arvidsson, W. Bauer, 2001, Chemistry.

2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.

G. Rummel, S. Cowan-Jacob, E. Vangrevelinghe, 2011, Bioorganic & medicinal chemistry letters.

Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

W. Sellers, R. Levine, F. Hofmann, 2012, Cancer discovery.

Genetic resistance to JAK 2 enzymatic inhibitors is overcome by HSP 90 inhibition

D. Erdmann, M. McKeown, J. Bradner, 2012 .

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

P. Furet, C. Leblanc, Christine C Genick, 2017, MedChemComm.

Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (+)-migrastatin.

Xin-Yun Huang, Dandan Shan, S. Danishefsky, 2004, Journal of the American Chemical Society.

En Route to the Total Synthesis of Tashironin: The Exercise of Stereochemical Control by a Methyl Group in Mediating Remote Cyclization Reactions.

S. Danishefsky, C. Gaul, S. Cook, 2005 .

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

The migrastatin family: discovery of potent cell migration inhibitors by chemical synthesis.

Jon T. Njardarson, William P. Tong, Xin-Yun Huang, 2004, Journal of the American Chemical Society.

Evolution of Novartis' Small Molecule Screening Deck Design.

A. Schuffenhauer, Eugen Lounkine, N. Stiefl, 2020, Journal of medicinal chemistry.

Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking Approach.

Philipp Holzer, R. Tiedt, G. Caravatti, 2017, ACS medicinal chemistry letters.

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.

R. Tiedt, C. Fernández, C. Scheufler, 2016, ACS medicinal chemistry letters.

DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway

E. Billy, D. Ruddy, F. Hofmann, 2020, Oncotarget.

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

W. Sellers, N. Socci, A. Viale, 2015, Cancer Cell.

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

P. Furet, C. Leblanc, Christine C Genick, 2017, MedChemComm.

2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.

G. Rummel, S. Cowan-Jacob, E. Vangrevelinghe, 2011, Bioorganic & medicinal chemistry letters.

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.

Philipp Holzer, R. Tiedt, G. Caravatti, 2016, ACS medicinal chemistry letters.